Lobbying Governance
| Overall Assessment | Analysis | Score |
|---|---|---|
| Moderate |
Wuxi Biologics has established a board-approved commitment to align its public policy engagement with the goals of the Paris Agreement and has implemented a recurring review process for its external climate advocacy. For instance, “We are committed to following public policies related to climate change that align with the Paris Agreement,” and “A reviewing and monitoring process was set up to continually assess whether our public policy engagement and collaborations are aligned with the Paris Agreement.” The company further notes that “This policy has been reviewed and approved by the Company’s Board of Directors to ensure its alignment with our climate strategy,” while the ESG Committee “conducts annual reviews of the Company’s climate-change strategy and performance to ensure that relevant rules and activities are successfully implemented and managed.” However, the company does not disclose any specific mechanisms for overseeing direct lobbying activities or criteria for assessing and aligning the positions of trade associations, nor does it identify an individual or formal body dedicated solely to lobbying‐alignment oversight beyond general ESG governance.
View Sources
|
C |